http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
송관규 대한류마티스 건강전문학회 1997 근관절건강학회지 Vol.4 No.2
Chronic fatigue syndrome is a syndrome of unknown etiology and pathophysiology characterized by severe, chronic, debilitating fatigue as main symptom and numerous additional symptoms such as joint and muscle pain, headache, sleep disturbance. According to recent researches, it was suggested that chronic fatigue syndrome was developed by disturbance of interaction between neuropsychiatric system and immune system due to environmental factors and stress. Many patients experience gradual improvement but complete recovery from disorderd state is rare. There was no research elucidating the exact pathogenetic mechanism of chronic fatigue syndrome, so there was no established treatment. Several controlled studies about treatment was reported , but its results was not effective in all patients with chronic fatigue syndrome. For chronic fatigue syndrome, a comprehensive approach to physical, psychological, and social aspects is needed.
전신성 홍반성 낭창 환자에서 유리형 Fas 단백질에 대한 연구
송관규 ( Gwan Gyu Song ),이영호 ( Young Ho Lee ) 대한류마티스학회 1996 대한류마티스학회지 Vol.3 No.1
전신성 홍반성 낭창의 발병기전에 대한 연구의 일환으로 전신성 홍반성 낭창 환자에서 유리형 Fas 단백질의 존재 여부를 확인함에 있다. 대상 및 방법: 30명의 전신성 홍반성 낭창 환자를 대상으로 하였으며 섬유조직염으로 진단받은 11명의 환자를 대조군으로 하였다. 환자의 대조군에서 모두 혈청을 채취하여 70℃의 냉장고에 보관한 후 sandwich ELISA 방법으로 동시에 측정하였다. 결과: 1. 전신성 홍반성 낭창 환자 30명중 6명(20%), 대조군은 11명중 1명(9.%)에서 양성으로 검사되어 전신성 홍반성 낭창 환자에서 양성율이 높은 경향을 보였다(p=0.41). 2. 환자의 연령은 sFas 양성인 군과 음성군간에 차이가 없었으나 sFas 양성군에서 이환기간이 짧고 질병의 활성도도 sFas 양성군에서 의미있게 높았으며 부신피질 호르몬의 투여량도 의미있게 낮았다. 3. 전신성 홍반성 낭창 환자를 다시 이환 기간 1개월 이하와 그 이상으로 나누어보면 1개월 이하의 이환 기간을 가진 12명중 6명(50%)에서 sFas가 검출되었고 1개월 이상의 이환 기간을 가진 18명의 환자에서는 1명도 sFas가 검출되지 않았다(p-0.0008, Table 2). 4. 전신성 홍반성 낭창 환자중 이환 기간이 1개월 이하인 환자 12명을 대상으로 sFas 양성과 음성의 2군으로 나누어 분서하면 2군간의 나이, 부신피질 호르몬의 투여용량, 질병의 활성도는 모두 차이가 없었으나 부신피질 호르몬의 투여용량은 sFas 양성군에서 적은 경향을 보였다(p=0.07). 결론: 이상의 결과로 이환 기간이 짧고 질병의 활동성이 높은 전신성 홍반성 낭창의 일부 환자에서는 혈중 유리형 Fas단백질이 증가되어 있고 유리형 Fas단백질에 의하여 apoptosis의 장애가 발생할 가능성이 있을 것으로 생각된다. Objective: To investigate soluble Fas(sFas) protein in the sera of patients with systemic lupus erythematosus (SLE). Methods: sFas protein was measured by sandwich ELISA method in the sera of 30 patients with SLE (mean age: 27.4±8.46, F:M=29:1) and 11 patients with fibromyalgia (mean age 35.8±11.5, F:M-11:0) as a control group. Results: sFas was elevated in 6 (20%) patients of SLE and 1 (9%) of patients with fibromyalgia (p=0.41). sFas level was correlated with a shorter duration, lower dosage of systemic steroid and higher disease activity in patients with elevated sFas levlel compared to patients with normal serum levels of sFas. All patients with elevated sFas had been diagnosed with SLE for less than 1 month. Fifty % (6 out of 12) patients with SLE for less than 1 month showed elevated sFas in serum. There was no difference of in the age between patients with elevated and normal levels of sFas. Conclusion: These data indicate that elevated sera levels of sFas was associated with the early active phase of disease in some patients with SLE and may play a role in defective apoptosis.
송관규(Gwan Gyu Song),정문기(Moon Gi Chung),권오상(Oh Sang Kwon),박창규(Chang Gyu Park),백세현(Sei Hyun Baik),서홍석(Hong Seog Seo),오동주(Dong Joo Oh),이창홍(Chang Hong Lee),원남희(Nam Hee Won) 대한내과학회 1995 대한내과학회지 Vol.48 No.5
N/A Temporal arteritis is an inflammatory disease of the elastic artery with unknown etiology. It usually affects patients over the age of 50, and is often associated with polymyalgia rheumatica. We have experienced a 66-year-old female patient with temporal arteritis who presented as a new onset headache and temporal artery abnormalities. Temporal artery biopsy was performed, which showed typical findings of temporal arteritis. To our knowledge, this is the first case of temporal arteritis in Korea. We hereby report a case of temporal arteritis with a brief review of literature.
경증 및 중등도 고혈압에서 Captopril 소량요법의 강압효과
송관규(Gwan Gyu Song),박창규(Chang Gyu Park),오동주(Dong Joo Oh),노영무(Young Moo Ro) 대한내과학회 1988 대한내과학회지 Vol.34 No.2
N/A The efficacy and safety of oral captopril, an angiotensin-converting enzyme inhibitor, were in 19 Korea patients (10 males, 9 females) with mild to moderate essential hypertension. The subjects with a sitting blood pressure of 140-189mmHg (systolic) and 95-114mmHg (diastolic) 2 weeks after the first blood pressure measurement while off all antihypertensive agents were enrolled in the study and were received captopril 25 mg bid for 6 weeks, b1ood pressure being measured every 2 weeks. Captopril significantly reduced systolic pressure from 161.6±14.6 to 146.6±15.5mmHg, diastolic pressure from 101.8±6.1 to 90.8±7.9mmHg, and mean pressure from 121.8±4.3 to 109.8±7.9mmHg (mean±SD, P<0.001 vs post-treatment 6th week blood pressure). Fall in systolic and diastolic pressure was 15.5±14.4mmHg and 11.1±9.5mmHg, respectively. In 66.6% diastolic blood pressure and in 37.5% systolic blood pressure were normalized. Side effects were noted in 2 cases (10.5%). One case showed transient elevation of transaminase level and the other headache, These findings suggest that low-dose captopril is an effective and safe first-line monotherapy for mild to moderate eseential hypertension.